

## sawai Group Safety Policy

Sawai Group shall establish a robust Pharmacovigilance System based on the sawai Corporate Philosophy and the sawai Code of Conduct to ensure the effective and proper operation of product safety-related activities. All Sawai Group officers and employees shall maintain close and timely communication with stakeholders on matters related to product safety, and shall contribute to preserve patient safety by involvement in product safety-related activities under our Pharmacovigilance System.

Our commitments are:

1. To ensure proper and safe use of our products by conducting safety surveillance and investigations, and effectively managing risks throughout the product life cycle
2. To comply with relevant safety-related regulations of the regions where our products are developed and marketed, and to provide regulatory authorities with complete and accurate information in a timely manner
3. To enhance the awareness of drug safety through continued training of all officers, employees, and relevant vendors
4. To monitor benefit / risk balance for our products by thoughtful and objective evaluation of safety information
5. To provide information on proper use of our products based on the latest medical / scientific evidence

Sawai Group officers shall demonstrate commitment to support the Pharmacovigilance System.

Supplementary Provisions

This Policy shall be under the jurisdiction of the Group Chief Quality & Safety Officer of Sawai Group Holdings.

The amendment and repeal of this Policy shall require the resolution of the Sawai Group Holdings Board of Directors.

Enacted and enforced on September 26, 2017

Revised and enforced on April 1, 2021

※Due to the transformation of Sawai Pharmaceutical into a holding company, the former Group policies of Sawai have been partially replaced and applied.